🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy

Recruitingn/aAges 18 Years - anyAllUniversity of Bonn
NCT07150000 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The CARe RAiSE project represents a pioneering translational initiative aimed at advancing precision medicine in the treatment of autoimmune rheumatic diseases. The primary objective is the development and implementation of an innovative cell-based ex vivo assay that enables individualized prediction of therapeutic response to disease-modifying antirheumatic drugs (DMARDs). By identifying the most effective treatment option for each patient, this approach seeks to enhance therapeutic efficacy, reduce time to clinical response, and minimize healthcare costs. Despite the availability of numerous DMARDs, clinical decision-making remains largely empirical due to considerable interindividual variability in treatment response. This frequently results in a prolonged trial-and-error process, placing a significant burden on patients and the healthcare system. CARe RAiSE aims to overcome this lim

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Participants aged ≥ 18 years * Signed written informed consent to participate voluntarily in the study. * Confirmed diagnosis (by the treating physician) of one of the following autoimmune or autoinflammatory rheumatic diseases: * Rheumatoid arthritis (RA) * Psoriatic arthritis (PsA) * Axial spondyloarthritis (axSpA) * Giant cell arteritis (GCA) * Connective tissue diseases, including: 1. Systemic lupus erythematosus (SLE) 2. Systemic sclerosis (SSc) 3. Mixed connective tissue disease (MCTD) 4. Idiopathic inflammatory myopathies (IIM) * ANCA-associated vasculitides (AAV), including: 1. Microscopic polyangiitis (MPA) 2. Granulomatosis with polyangiitis (GPA) 3. Eosinophilic granulomatosis with polyangiitis (EGPA) * Autoinflammatory diseases, including 1. Familial Mediterranean fever (FMF) 2. Cryopyrin-associated periodic syndromes (CAPS) 3. TNF receptor-associated periodic syndrome (TRAPS) 4. Adult-onset Still's disease (AOSD) Exclusion Criteria: * Refusal to participate in the study or inability to provide informed consent. Inclusion Criteria - Healthy Control Group: * Participants aged ≥ 18 years (capable of providing informed consent). * Signed written informed consent to participate voluntarily in the study. Exclusion Criteria - Healthy Control Group: \- Presence of a known or active rheumatologic disease.
💊

What it tests

  • Ex Vivo Assay
📍

Where

1 site
University Hospital, Bonn
Bonn, Germany
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy